{"protocolSection":{"identificationModule":{"nctId":"NCT03024476","orgStudyIdInfo":{"id":"B-1604/343"},"organization":{"fullName":"Seoul National University Bundang Hospital","class":"OTHER"},"briefTitle":"Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance","officialTitle":"Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance: Prospective, Randomized, Open, Blinded Outcome Evaluation, and Feasibility Trial"},"statusModule":{"statusVerifiedDate":"2018-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-07","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12-07","type":"ACTUAL"},"studyFirstSubmitDate":"2017-01-03","studyFirstSubmitQcDate":"2017-01-16","studyFirstPostDateStruct":{"date":"2017-01-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-04-04","lastUpdatePostDateStruct":{"date":"2018-04-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hee-Joon Bae","investigatorTitle":"Professor","investigatorAffiliation":"Seoul National University Bundang Hospital"},"leadSponsor":{"name":"Seoul National University Bundang Hospital","class":"OTHER"},"collaborators":[{"name":"Daiichi Sankyo Korea Co., Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"BOSS-Trial I is a phase 2 clinical trial with the following objectives;\n\n1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server;\n2. to prove the feasibility of the BP management strategy, including the pre-specified BP range, BP management algorithm, and behavioral; and\n3. to gather information for the phase 3 trial including BP variability indices and their potentials as a treatment guidance.","detailedDescription":"* Elevated blood pressure is an established risk factor for recurrent stroke and vascular events in ischemic stroke survivors, but\n* Current guideline (JNC VIII) has omitted or only partially covered a number of practical and important issues as follow;\n\n  * When and how we measure blood pressure?\n  * Is it justifiable to apply the same blood pressure threshold for office BP and home BP?\n  * Should stroke survivors be treated by the same BP goal for non-stroke subjects?\n  * Is it justifiable to apply the universal BP threshold for different mechanisms of ischemic stroke?\n  * Is it really about only blood pressure or might it really be \"beyond blood pressure?\"\n* Lifestyle modification should accompany all the pharmacological intervention but is usually in adequate to initiate behavioral changes.\n* Frequent BP measurement at home will provide more detailed and reliable information than occasional office BP's."},"conditionsModule":{"conditions":["Ischemic Stroke","Hypertension"],"keywords":["behavioral intervention","prespecified medication algorithm","bluetooth-equipped sphygmomanometer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":67,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Intensive management arm","type":"EXPERIMENTAL","description":"Description:\n\n* Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan\n* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).\n* Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.\n* Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.","interventionNames":["Behavioral: Behavioral intensification","Drug: Pharmacological intensification based on olmesartan","Device: Bluetooth-equipped sphygmomanometer"]},{"label":"Control arm","type":"ACTIVE_COMPARATOR","description":"Description:\n\n* Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.\n* Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).","interventionNames":["Device: Bluetooth-equipped sphygmomanometer"]}],"interventions":[{"type":"BEHAVIORAL","name":"Behavioral intensification","description":"Suggested algorithm for behavioral intensification:\n\n* If frequency of BP measurement ≤5 in a week, send a texting message\n* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse\n* Target range of home-systolic blood pressure: 110 - 135\n* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)\n* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management","armGroupLabels":["Intensive management arm"]},{"type":"DRUG","name":"Pharmacological intensification based on olmesartan","description":"* Study drug will be provided from the roll-in period.\n* Step I:\n\n  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days\n  * Use olmesartan 40 mg if mean systolic blood pressure \\>150 during the immediate past 2 days\n* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg\n* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg\n* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg\n* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.\n* Use of beta-blockers is permitted if clinically indicated.\n* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule.","armGroupLabels":["Intensive management arm"]},{"type":"DEVICE","name":"Bluetooth-equipped sphygmomanometer","description":"* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)\n* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)","armGroupLabels":["Control arm","Intensive management arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Recruitment time to prespecified number of subjects","description":"Difference in days between recruitment of the first subject and last subject","timeFrame":"At 3 months after randomization"},{"measure":"Retention of included participants","description":"Ratio of completed subject over randomized subjects in each group","timeFrame":"At 3 months after randomization"},{"measure":"Frequencies of calls for breakthrough visit","description":"Mean and standard deviation of breakthrough visits per each patient in the intensive management group","timeFrame":"At 3 months after randomization"},{"measure":"Rate of patients who responded to the calls for breakthrough visit","description":"ratio of subjects response over the breakthrough visit calls","timeFrame":"At 3 months after randomization"},{"measure":"Control of blood pressure","description":"ratio of subjects with well-controlled BP in each group","timeFrame":"At 3 months after randomization"}],"secondaryOutcomes":[{"measure":"Frequency of out-of-range measurement","description":"Frequency of BP measurements out of the desirable BP range in a week","timeFrame":"At 3 months after randomization"},{"measure":"Weighted hit score of BP","description":"When two consecutive hits crossed over or below the margin of desirable BP, give 2x weight. Final score will be generated by dividing by total number of measurements","timeFrame":"At 3 months after randomization"},{"measure":"Vascular events","description":"Recurrent vascular events including recurrent stroke, myocardial infarction or vascular death","timeFrame":"At 3 months after randomization"},{"measure":"Hypotensive events","description":"Complaint of dizzy spells, falls or low-BP related events by patients","timeFrame":"Until 3 months after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ischemic stroke survivors within 7 days after onset\n* ≥19 year-old male or female\n* Medically and neurologically stabilized enough to take BP-lowering medication\n* Mean systolic blood pressure ≥135 mm Hg during two days between at least 24 hours after onset and randomization (whether BP-lowering medication was prescribed or not)\n* Capable of taking oral medication\n* Capable of operating a wireless Bluetooth-equipped sphygmomanometer system and being expected to follow required procedures of the clinical trial\n* Patients who provided written informed consent\n\nExclusion Criteria:\n\n* Pregnant, puerperium ≤30 days or on breastfeeding\n* enrolled in other interventional clinical trial\n* Being transferred to rehabilitation center or institutionalized\n* Being expected to have cerebral artery interventions within 3 months after randomization\n* Known allergic reactions to olmesartan, amlodipine or hydrochlorothiazide\n* Known severe hepatic disease\n* Advanced kidney dysfunction requiring dialysis\n* Being unlikely, in the opinion of the investigator, to comply with the clinical trial protocol or being unsuitable for any other reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Hee-Joon Bae, MD.PhD","affiliation":"Seoul National University Bundang Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","state":"Gyeonggi","zip":"13520","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Nowon Eulji Medical Center, Eulji University","city":"Seoul","zip":"01830","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Medical Center","city":"Seoul","zip":"02053","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"annotationSection":{"annotationModule":{"unpostedAnnotation":{"unpostedResponsibleParty":"Hee-Joon Bae, Professor, Seoul National University Bundang Hospital","unpostedEvents":[{"type":"RELEASE","date":"2022-05-03"},{"type":"RESET","date":"2023-02-02"}]}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2022-05-03","submissionInfos":[{"releaseDate":"2022-05-03","resetDate":"2023-02-02"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M9714","name":"Hypertension","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000437965","term":"Olmesartan"}],"ancestors":[{"id":"D000000959","term":"Antihypertensive Agents"},{"id":"D000047228","term":"Angiotensin II Type 1 Receptor Blockers"},{"id":"D000057911","term":"Angiotensin Receptor Antagonists"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M19290","name":"Amlodipine","relevance":"LOW"},{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"M3361","name":"Adrenergic beta-Antagonists","relevance":"LOW"},{"id":"M9600","name":"Hydrochlorothiazide","relevance":"LOW"},{"id":"M91712","name":"Olmesartan","asFound":"Burst","relevance":"HIGH"},{"id":"M273","name":"Olmesartan Medoxomil","relevance":"LOW"},{"id":"M3967","name":"Antihypertensive Agents","relevance":"LOW"},{"id":"M3822","name":"Angiotensin II","relevance":"LOW"},{"id":"M289298","name":"Giapreza","relevance":"LOW"},{"id":"M3825","name":"Angiotensinogen","relevance":"LOW"},{"id":"M25479","name":"Angiotensin II Type 1 Receptor Blockers","relevance":"LOW"},{"id":"M28606","name":"Angiotensin Receptor Antagonists","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"NaAg","name":"Natriuretic Agents"},{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}